Discussion: Further reduction of the overall IND rate could be achieved by including probes for alternative variants at the codons tested, such as M184I and G190S, depending on the frequency of these mutations in the target population.
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Abstract: Of the 96 PR/RT sequences analyzed, M184V/I (52/96; 54%) had the most frequent RAM nucleoside reverse transcriptase inhibitor (NRTI).
Result: M184V/I was also found in two (4%) patients receiving TDF plus 3TC, compared with those receiving FTC plus TDF (n = 1; 2%).
Result: M184V/I was detected in 52 (54%) patients suspected of failing cART.
Result: We observed M184V/I as the most prevalent NRTI
Discussion: Our findings correspond with previous studies conducted in South Africa with PLHIV, showing M184V/I as the most prevalent NRTI mutation.
HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Abstract: The leading DRMs observed in the study were M184I/V (59.59%) against NRTIs and K103N (37.55%) against NNRTIs.
Discussion: NRTI-associated DRMs M184I/V and K65R and NNRTI-associated DRMs with extensively drug resistance K101E/H/P, V179I/D/E/T, Y181C/V, and
Discussion: In our study, M184I/V (59.59%) was the most prevalent mutation associated with NRTI resistance in our study and was also frequently found in Europe, Africa, and other regions in China.
HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
Abstract: NRTI and NNRTI associated dominant mutations were M184I/V and K103 N.High-level resistance to lamivudine (3 TC) and Emtricitabine (FTC) were detected in 34.3% of patients while 53.1% were resistant to Efavirenz (EFV) and Nevirapine (NVP).
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
Abstract: Baseline next-generation sequencing detected lamivudine resistance mutations (M184V/I and/or K65R/E/N) over a 5% threshold in 15/21 (71 4%) and 3/20 (15%) of participants with and without history of lamivudine resistance, respectively.
Result: Among participants without historical lamivudine resistance, none presented the K65R/E/N mutation but in three and seven cases the M184I mutation was detected with over a 5% or 1% threshold, respectively, including one participant harboring the M184I mutation with a 99% frequency.
Result: Seven participants with historical lamivudine resistance had the M184V/I and/or K65R/E/N mutations detected over the 20% threshold at baseline by next generation sequ
High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
PMID: 32413134
2020
The Journal of antimicrobial chemotherapy
Abstract: A plasma historical genotypic report (HGR) showing the presence of M184V/I was required for all participants and proviral HIV DNA analysis was conducted prior to enrolment.
Abstract: BACKGROUND: The M184V/I reverse transcriptase mutation, which confers major resistance to lamivudine and emtricitabine, is still quite frequent in people living with HIV.
Abstract: CONCLUSIONS: Our results suggest that undetected M184V/I should be considered when switching virologically suppressed patients to new regimens, particularly two-drug lamivudine- or emtricitabine-containing combinations.
Abstract: Differential detection of M184V/I was not associated with timing differences between the HGR and proviral HIV DNA sampling, the overall duration of ART, or CD4 cell counts and HIV
High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda.
PMID: 32475121
2020
AIDS research and human retroviruses
Abstract: The mutation K103N was detected in 62.5% (30/48) of participants, 41.7% (20/48) had M184V/I, 14.6% had K65R, and 12.5% (6/48) had thymidine analog mutations (TAMs).
Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries.
PMID: 32522826
2020
Journal of clinical microbiology
Abstract: In a cross-sectional study (June 2018 to September 2019), we evaluated the diagnostic accuracy of a simple and rapid HIVDR assay (the pan-degenerate amplification and adaptation [PANDAA] assay targeting the mutations K65R, K103NS, M184VI, Y181C, and G190A) compared to Sanger sequencing and next-generation sequencing (NGS).
Abstract: PANDAA showed strong agreement with Sanger sequencing for K65R, K103NS, M184VI, and G190A (kappa > 0.85) and substantial agreement for Y181C (kappa = 0.720).
HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.
Introduction: Patients failing an NNRTI-based first-line regimen with genotypic drug resistance mutations typically present with M184V/I, K65R, and/or thymidine analogue mutations (TAMs) and K103N, V106M/A and/or Y181C as the most prevalent NRTI and NNRTI mutations, respectively.
Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study.
Abstract: The most common mutations in NNRTIs, NRTIs and PIs were K103N/KN (64.69%), M184V/MV/I (36.29%) and Q58E/QE (4.93%), respectively.
Result: The most common mutations in NNRTIs were K103N/KN (64.69%), V179D/E (23.47%) and Y181C/YC/I (14.00%), they were M184V/MV/I (36.29%), T215F/FS/TNSY (7.50%) and K219Q (5.92%) in NRTIs, and they were Q58E/QE (4.93%),
ViMRT
HIV mutation literature information.
PMID: 
2020
AIDS (London, England)
